Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guides
Guidance and tools
Shares
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks Stock plan guidance
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
Life Science REIT reports fall in portfolio value amid strategic review
(Sharecast News) - Life Science REIT reported a 10.9% fall in the value of its portfolio during the first half of 2025 on Monday, amid ongoing uncertainty in the life sciences real estate market and slower-than-expected leasing activity. The London-listed real estate investment trust said its unaudited EPRA net tangible assets as at 30 June stood at £232.1m, or 66.3p per share, down from £260.4m, or 74.4p, at the end of 2024.
It said the decline in valuation was broadly consistent across the company's five assets, reflecting wider market pressures and outward yield movement, particularly for assets with existing vacancy.
The update came as it continued to evaluate its strategic options, including a possible managed wind-down or a sale.
Its board said it had received a "significant amount of interest" since launching the formal sale process in March, with certain parties granted access to due diligence materials and meetings with its investment adviser, Ironstone Asset Management.
At the same time, the board was also reviewing potential returns from an orderly asset disposal programme.
Operationally, Life Science REIT said it had made modest progress on leasing, with four new tenants signed in 2025, increasing contracted rent to £17.4m and occupancy to 85.1%, compared to £15.9m and 84.4% at the end of December.
Notable deals included a lease at Unit 9 of the Innovation Quarter at Oxford Technology Park (OTP) and the full letting of Rolling Stock Yard following an agreement with Wayve Technologies.
At OTP, the company said it had also agreed a redesign of the final development phase with its partner Oxtec.
Buildings 10 and 11 would now comprise seven smaller lab units rather than two large structures, to meet stronger demand for flexible space.
The change was expected to lift estimated rental value by £0.35m to £2.1m, although it would incur an additional £5m in development costs.
Planning would follow shortly, the board said, with construction to begin once permission was granted.
Elsewhere at OTP, construction of Buildings 6 and 7 completed in the first half, while Buildings 8 and 9 were nearing completion.
Work was also underway on a new café and amenity space, due to open early in the fourth quarter.
The company confirmed a minor technical breach of a bank covenant during the period, with the projected interest cover ratio at 193.1% versus the required 200%.
A waiver had been secured from lenders, who the firm said remained supportive of the business through the review process.
Life Science REIT said it opted not to implement additional hedging, citing the ongoing strategic review.
At 1145 BST, shares in Life Science REIT were down 7.11% at 40.5p.
Reporting by Josh White for Sharecast.com.
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity, Equity & Inclusion | Diversity, Equity & Inclusion Reports | Doing Business with Fidelity | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Staying secure | Statutory and Regulatory disclosures | Whistleblowing programme
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.